Trial Profile
A reterospective study to evaluate dynamic-susceptibility contrast MRI to measures relative cerebral blood volume response to bevacizumab in recurrent high-grade glioma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 05 Dec 2015 New trial record